S&P 500   3,276.24 (+1.01%)
DOW   28,722.85 (+0.66%)
QQQ   221.45 (+1.54%)
AAPL   317.69 (+2.83%)
FB   217.79 (+1.36%)
MSFT   165.46 (+1.96%)
GOOGL   1,450.50 (+1.31%)
AMZN   1,853.25 (+1.36%)
CGC   23.92 (+10.95%)
NVDA   247.97 (+3.23%)
BABA   210.23 (+2.32%)
MU   56.47 (+1.91%)
GE   11.73 (+2.53%)
TSLA   566.90 (+1.59%)
AMD   50.53 (+2.58%)
T   38.58 (+0.86%)
ACB   1.97 (+4.23%)
F   8.97 (+0.90%)
NFLX   348.52 (+1.64%)
PRI   120.64 (+1.31%)
BAC   33.24 (+1.19%)
DIS   138.37 (+1.82%)
GILD   64.36 (+0.83%)
S&P 500   3,276.24 (+1.01%)
DOW   28,722.85 (+0.66%)
QQQ   221.45 (+1.54%)
AAPL   317.69 (+2.83%)
FB   217.79 (+1.36%)
MSFT   165.46 (+1.96%)
GOOGL   1,450.50 (+1.31%)
AMZN   1,853.25 (+1.36%)
CGC   23.92 (+10.95%)
NVDA   247.97 (+3.23%)
BABA   210.23 (+2.32%)
MU   56.47 (+1.91%)
GE   11.73 (+2.53%)
TSLA   566.90 (+1.59%)
AMD   50.53 (+2.58%)
T   38.58 (+0.86%)
ACB   1.97 (+4.23%)
F   8.97 (+0.90%)
NFLX   348.52 (+1.64%)
PRI   120.64 (+1.31%)
BAC   33.24 (+1.19%)
DIS   138.37 (+1.82%)
GILD   64.36 (+0.83%)
S&P 500   3,276.24 (+1.01%)
DOW   28,722.85 (+0.66%)
QQQ   221.45 (+1.54%)
AAPL   317.69 (+2.83%)
FB   217.79 (+1.36%)
MSFT   165.46 (+1.96%)
GOOGL   1,450.50 (+1.31%)
AMZN   1,853.25 (+1.36%)
CGC   23.92 (+10.95%)
NVDA   247.97 (+3.23%)
BABA   210.23 (+2.32%)
MU   56.47 (+1.91%)
GE   11.73 (+2.53%)
TSLA   566.90 (+1.59%)
AMD   50.53 (+2.58%)
T   38.58 (+0.86%)
ACB   1.97 (+4.23%)
F   8.97 (+0.90%)
NFLX   348.52 (+1.64%)
PRI   120.64 (+1.31%)
BAC   33.24 (+1.19%)
DIS   138.37 (+1.82%)
GILD   64.36 (+0.83%)
S&P 500   3,276.24 (+1.01%)
DOW   28,722.85 (+0.66%)
QQQ   221.45 (+1.54%)
AAPL   317.69 (+2.83%)
FB   217.79 (+1.36%)
MSFT   165.46 (+1.96%)
GOOGL   1,450.50 (+1.31%)
AMZN   1,853.25 (+1.36%)
CGC   23.92 (+10.95%)
NVDA   247.97 (+3.23%)
BABA   210.23 (+2.32%)
MU   56.47 (+1.91%)
GE   11.73 (+2.53%)
TSLA   566.90 (+1.59%)
AMD   50.53 (+2.58%)
T   38.58 (+0.86%)
ACB   1.97 (+4.23%)
F   8.97 (+0.90%)
NFLX   348.52 (+1.64%)
PRI   120.64 (+1.31%)
BAC   33.24 (+1.19%)
DIS   138.37 (+1.82%)
GILD   64.36 (+0.83%)
Log in

NASDAQ:GEMP - Gemphire Therapeutics Stock Price, Forecast & News

$8.35
+0.14 (+1.71 %)
(As of 01/28/2020 04:00 PM ET)
Today's Range
$7.95
Now: $8.35
$8.37
50-Day Range
$0.27
MA: $4.75
$9.26
52-Week Range
$0.24
Now: $8.35
$1.49
Volume9,539 shs
Average Volume116,318 shs
Market Capitalization$124.16 million
P/E RatioN/A
Dividend YieldN/A
Beta2.82
Gemphire Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GEMP
CUSIPN/A
Phone734-245-1700

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.54 per share

Profitability

Net Income$-23,640,000.00

Miscellaneous

Employees9
Market Cap$124.16 million
Next Earnings DateN/A
OptionableOptionable

Receive GEMP News and Ratings via Email

Sign-up to receive the latest news and ratings for GEMP and its competitors with MarketBeat's FREE daily newsletter.


Gemphire Therapeutics (NASDAQ:GEMP) Frequently Asked Questions

What is Gemphire Therapeutics' stock symbol?

Gemphire Therapeutics trades on the NASDAQ under the ticker symbol "GEMP."

How were Gemphire Therapeutics' earnings last quarter?

Gemphire Therapeutics Inc (NASDAQ:GEMP) released its quarterly earnings data on Friday, March, 15th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.41) by $0.15. View Gemphire Therapeutics' Earnings History.

What is the consensus analysts' recommendation for Gemphire Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gemphire Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Gemphire Therapeutics.

Has Gemphire Therapeutics been receiving favorable news coverage?

Press coverage about GEMP stock has been trending positive this week, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Gemphire Therapeutics earned a media sentiment score of 3.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Gemphire Therapeutics.

Who are some of Gemphire Therapeutics' key competitors?

What other stocks do shareholders of Gemphire Therapeutics own?

Who are Gemphire Therapeutics' key executives?

Gemphire Therapeutics' management team includes the folowing people:
  • Dr. Charles L. Bisgaier, Co-Founder, Chairman & Chief Scientific Officer (Age 65)
  • Dr. Steven R. Gullans, CEO, Pres, Director, Principal Financial Officer & Principal Accounting Officer (Age 66)
  • Mr. Seth Reno, Chief Commercial Officer (Age 52)
  • Mr. Jeffrey S. Mathiesen C.P.A., CPA, Consultant (Age 58)
  • Ms. Amy Zaremba Rabourn, Director of Fin.

When did Gemphire Therapeutics IPO?

(GEMP) raised $30 million in an initial public offering on Friday, August 5th 2016. The company issued 3,000,000 shares at $10.00 per share. Jefferies and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity and Roth Capital Partners were co-managers.

How do I buy shares of Gemphire Therapeutics?

Shares of GEMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Gemphire Therapeutics' stock price today?

One share of GEMP stock can currently be purchased for approximately $8.35.

How big of a company is Gemphire Therapeutics?

Gemphire Therapeutics has a market capitalization of $124.16 million. Gemphire Therapeutics employs 9 workers across the globe.View Additional Information About Gemphire Therapeutics.

What is Gemphire Therapeutics' official website?

The official website for Gemphire Therapeutics is http://www.gemphire.com/.

How can I contact Gemphire Therapeutics?

Gemphire Therapeutics' mailing address is 17199 N. LAUREL PARK DRIVE SUITE 401, LIVONIA MI, 48152. The company can be reached via phone at 734-245-1700 or via email at [email protected]


MarketBeat Community Rating for Gemphire Therapeutics (NASDAQ GEMP)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  276 (Vote Outperform)
Underperform Votes:  237 (Vote Underperform)
Total Votes:  513
MarketBeat's community ratings are surveys of what our community members think about Gemphire Therapeutics and other stocks. Vote "Outperform" if you believe GEMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GEMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel